NEXIUM IV Drug Patent Profile
✉ Email this page to a colleague
When do Nexium Iv patents expire, and what generic alternatives are available?
Nexium Iv is a drug marketed by Astrazeneca and is included in one NDA.
The generic ingredient in NEXIUM IV is esomeprazole sodium. There are seventy-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the esomeprazole sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nexium Iv
A generic version of NEXIUM IV was approved as esomeprazole sodium by EUGIA PHARMA on August 10th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEXIUM IV?
- What are the global sales for NEXIUM IV?
- What is Average Wholesale Price for NEXIUM IV?
Summary for NEXIUM IV
Recent Clinical Trials for NEXIUM IV
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Alexandria University | Phase 3 |
Nanfang Hospital of Southern Medical University | Phase 4 |
Liaocheng People's Hospital | Phase 1 |
Pharmacology for NEXIUM IV
Drug Class | Proton Pump Inhibitor |
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors |
Paragraph IV (Patent) Challenges for NEXIUM IV
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NEXIUM IV | For Injection | esomeprazole sodium | 20 mg/vial and 40 mg/vial | 021689 | 1 | 2009-11-23 |
US Patents and Regulatory Information for NEXIUM IV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-001 | Mar 31, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-002 | Mar 31, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NEXIUM IV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-001 | Mar 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-002 | Mar 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-002 | Mar 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-001 | Mar 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NEXIUM IV
See the table below for patents covering NEXIUM IV around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Singapore | 49283 | New compounds | ⤷ Sign Up |
Portugal | 1020460 | ⤷ Sign Up | |
Cyprus | 2224 | Optically pure salts of pyridinylmethyl sulfinyl-1H-benzimidazole compounds | ⤷ Sign Up |
Hong Kong | 1028045 | ⤷ Sign Up | |
Morocco | 23210 | ⤷ Sign Up | |
Poland | 307261 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NEXIUM IV
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1411900 | 2011/016 | Ireland | ⤷ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
1411900 | 2011C/016 | Belgium | ⤷ Sign Up | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
0984957 | SPC/GB11/013 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
1020461 | 91870 | Luxembourg | ⤷ Sign Up | |
0124495 | SPC/GB01/006 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
1020461 | C300482 | Netherlands | ⤷ Sign Up | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |